Archive

Human papilloma virus (HPV) vaccination in perspective

Written by Christine Clark | 12 Mar 2021

Interview and article by Christine Clark In the first ten years of the UK national HPV vaccination programme more than ten million doses of HPV vaccine were given… read more.

EMA plans rapid approval of vaccines against COVID-19 variants

Written by Gary Finnegan | 12 Mar 2021

Article written by Gary Finnegan. New COVID-19 vaccines against variants of the virus could be approved much more quickly than the first generation of jabs. The European Medicines… read more.

Human papilloma virus (HPV) vaccines and vaccination strategy

Written by Christine Clark | 11 Mar 2021

Interview and article by Christine Clark Dr Peter English, a consultant in communicable disease control describes the UK HPV vaccination strategy and the associated issues. Dr Peter English,… read more.

Vaccination potential will not be achieved without increased production, affordable pricing, global availability, and successful rollout

Written by Charlie King | 26 Feb 2021

To ensure an effective global immunisation strategy against COVID-19, vaccines need to be produced at scale, priced affordably, and allocated globally so that they are available where needed,… read more.

Pfizer and BioNTech submit COVID-19 vaccine stability data at standard freezer temperature to the FDA

Written by Charlie King | 23 Feb 2021

Pfizer Inc. and BioNTech SE announced the submission of new data to the FDA demonstrating the stability of their COVID-19 vaccine when stored at -25°C to -15°C (-13°F… read more.

WHO gives COVID-19 Vaccine AstraZeneca Emergency Use Listing for COVID-19 – AstraZeneca

Written by Charlie King | 21 Feb 2021

AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age… read more.

Phase III data update for CoronaVac in COVID-19 – Sinovac Biotech

Written by Charlie King | 18 Feb 2021

Sinovac Biotech has announced phase III results of CoronaVac in COVID-19 treatment.

Ivermectin mass treatment in perspective

Written by Christine Clark | 17 Feb 2021

Interview and article by Christine Clark. Ivermectin is a good treatment to use interim to and complementary to immunisations, according to Dr David Scheim, one of the authors… read more.

The Wits Vaccines and Infectious Diseases Analytics Research Unit, which runs the ChAdOx1 nCoV-19 vaccine trial in South Africa, has announced results

Written by Charlie King | 16 Feb 2021

In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the… read more.

Ivermectin dosing and distribution for mass treatment

Written by Christine Clark | 16 Feb 2021

Interview and article by Christine Clark. Dr David Scheim, one of the authors of a recent study in Peru, describes the doses of ivermectin that were used and… read more.

Results of using ivermectin for mass treatment

Written by Christine Clark | 15 Feb 2021

Interview and article by Christine Clark. Mature, real world data on systematic mass treatment of covid-19 with ivermectin show a sharp fall in excess deaths. IMI interviewed Dr… read more.

COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials

Written by Charlie King | 11 Feb 2021

The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is… read more.

« Previous 1 … 7 8 9 10 11 Next »

Archive

Subscribe for our mailing list

Follow Us